Biomaterials Firm Bolt Threads, Formerly A Unicorn, Plans SPAC Deal At A $250 Million Valuation

CEO Dan Widmaier talks exclusively with Forbes about going public and the ups and downs of running a synthetic biology firm.

Bolt Threads, a maker of biomaterials including a key ingredient for skincare inspired by spider silk, plans to go public in a SPAC deal that values the one-time unicorn at $250 million.

Support authors and subscribe to content

This is premium stuff. Subscribe to read the entire article.

Gain access to all our Premium contents.
More than 100+ articles.

Subscribe Now

Buy Article

Unlock this article and gain permanent access to read it.

Unlock Now

Biomaterials Firm Bolt Threads, Formerly A Unicorn, Plans SPAC Deal At A $250 Million Valuation

Related Articles

Pepsi: 1 App To Rule Them All, And In The Lightness Bind Them

Despite Turnover Issues, Josh Dobbs Deserves 1 More Start For Vikings

U2 Keeps Extending Their Concert Residency

Ukraine Has Formed A New Tank Brigade

Executive Sketch: Matheson Leads NRECA In Era of Big Change For Utilities

NASA’s Planned 2025 Moon Landing ‘Unlikely’ Amid SpaceX And Spacesuit Delays, Report Warns

2024 Political TV Advertising: We’re Ready To Project The Winners

Hamas Releases 2 Israeli-Russian Hostages In Outreach To Putin—As 6-Day Truce With Israel Nears End

Erik Ten Hag Challenges Facundo Pellistri To Step Up At Manchester United

Navigate Site

Welcome Back!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?

Biomaterials Firm Bolt Threads, Formerly A Unicorn, Plans SPAC Deal At A $250 Million Valuation

CEO Dan Widmaier talks exclusively with Forbes about going public and the ups and downs of running a synthetic biology firm.

Support authors and subscribe to content

Subscribe

Buy Article

Related Articles

Navigate Site

Follow Us

Welcome Back!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?